# A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

> **NCT00189813** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 691 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** YM060

## Key facts

- **NCT ID:** NCT00189813
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 691 (ACTUAL)
- **Last updated:** 2014-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189813, "A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00189813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*